Medeva PLC
Executive Summary
Merger discussions are ongoing with a third party, the company said. Previous discussions of a cash offer for the firm were terminated Sept. 17 (1"The Pink Sheet" Sept. 20, In Brief). At that time, the suitor was speculated to be Elan
You may also be interested in...
Celltech Chiroscience Acquisition Of Medeva Provides Marketing Muscle
Medeva will bring a sales force of 400 reps, including 180 reps in the U.S., to the proposed merger with Celltech Chiroscience.
Celltech Chiroscience Acquisition Of Medeva Provides Marketing Muscle
Medeva will bring a sales force of 400 reps, including 180 reps in the U.S., to the proposed merger with Celltech Chiroscience.
Medeva
Discussions of a cash offer for the firm "have now been terminated," Medeva announced Sept. 17. "The proposal received turned out to be at an opportunistic price which the board [of Medeva], advised by Lazard Brothers, had no hesitation in rejecting." Elan had been rumored to be the suitor (1"The Pink Sheet" Sept. 13, p. 4). At a Bear Stearns conference Sept. 15, Elan Exec VP-Business Development Michael Sember said that after several sizeable acquisitions in 1998, the company has been in a "breathing period...focusing on integrating these business units"